Abnormal glucose tolerance in CF - When should we offer diabetes treatment?

Pediatric Diabetes

Volumn 10, Issue 3, 2009, Pages 159-161

  Moran, Antoinette ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN GLARGINE; PLACEBO; REPAGLINIDE;

CAUSE OF DEATH; CELL DESTRUCTION; CLINICAL TRIAL; CYSTIC FIBROSIS; EDITORIAL; HEREDITY; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INFECTION; INFLAMMATION; INSULIN DEFICIENCY; INSULIN RESISTANCE; INSULIN TREATMENT; LUNG FUNCTION; LUNG INFECTION; MORBIDITY; MORTALITY; NUTRITIONAL STATUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RESPIRATORY FAILURE;

BLOOD GLUCOSE; CYSTIC FIBROSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS;

EID: 65449171179     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2009.00521.x     Document Type: Editorial

References (16)

1. Moran A, Hardin D, Rodman D et al. Diagnosis, screening, and management of CFRD: A consensus conference report. J Diabetes Res Clin Pract 1999: 45: 55-71
2. Couce M, O'Brien TD, Moran A, Roche PC, Butler PC. Diabetes mellitus in CF is characterized by islet amyloidosis. J Clin Endocrinol Metab 1996: 81: 1267-1272
3. Blackman SM, Hsu S, Vanscoy LL et al. Genetic modifiers play a substantial role in diabetes complicating cystic fibrosis. J Clin Endocrinol Metab 2009: Doi:10.1210/jc.2008-2186
4. Dobson L, Sheldon CD, Hattersley AT Conventional measures underestimate glycaemia in CF patients. Diabet Med 2004: 21: 691-696
5. Franzese D, Valerio G, Buono P et al. Continuous glucose monitoring system in the screening of early glucose derangements in children and adoelscents with CF. J Pediatr Endocrinol Metab 2008: 21: 109-116
6. Schwarzenberg SJ, Thomas W, Olsen TW et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care 2007: 30: 1056-1061
7. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in cystic fibrosis patients correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 2001: 162: 891-895
8. Brennan AL, Gyi KM, Wood DM et al. Airway glucose concentrations and effect on growth of respiratory pathogens in CF. J Cyst Fibros 2007: 6: 101-109
9. Lanng S, Thorsteinsson B, Nerup J, Koch C. Diabetes mellitus in cystic fibrosis: Effect of insulin therapy on lung function and infections. Acta Paediatr 1994: 83: 849-853
10. Franzese A, Spagnuolo MI, Sepe A, Valerio GEM, Raia V. Can glargine reduce the number of lung infections in patients with CFRD? Diabetes Care 2005: 28: 2333
11. Mohan K, Miller H, Burhan H, Ledson MJ, Walshaw MN. Management of CFRD: a survey of UK cystic fibrosis centers. Pediatr Pulmonol 2008: 43: 642-647
12. Nousia-Arvanitakis S, Galli-Tsinopoulou A, Karamouzis M. Insulin improves clinical status of patients with cystic fibrosis-related diabetes mellitus. Acta Paediatr 2001: 90: 515-519
13. Rolon MA, Benali K, Munck A et al. CFRD: Clinical impact of prediabetes and effects of insulin therapy. Acta Paediatr 2001: 90: 860-867
14. Zipf WB, Kien CL, Horswill CA, McCoy KS, O'Dorisio T, Pinyerd BL. Effects of tolbutamide on growth and body composition of nondiabetic children with CF. Pediatr Res 1991: 30: 309-314
15. Bizzarri C, Lucidi V, Ciampalini P, Bella S, Russo B, Cappa M. Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance. J Endocrinol Invest 2006: 29: RC1-4
16. Mozzillo E, Franzese A, Valerio G et al. One year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements. Pediatr Diabetes 2009: 10: 162-167